Table 2.
Characteristics of patients who had <50% programmed cell death-1 ligand-1 positivity
| Characteristics | Total n = 32 |
ATA-negative n = 22 |
ATA-positive n = 10 |
p value |
| Age (years) | 68 ± 10 | 73 ± 6 | 62 ± 11 | 0.163 |
| <70 | 14 | 10 | 4 | 1.000 |
| ≥70 | 18 | 12 | 6 | |
| Sex | ||||
| Female | 7 | 5 | 2 | 1.000 |
| Male | 25 | 17 | 8 | |
| BMI (kg/m2) | 22 ± 3 | 21 ± 4 | 22 ± 2 | 0.703 |
| <25 | 26 | 18 | 8 | 1.000 |
| ≥25 | 6 | 4 | 2 | |
| Drugs | ||||
| Nivolumab | 18 | 15 | 3 | 0.062 |
| Pembrolizumab | 14 | 7 | 7 | |
| Tumor histology | ||||
| SCC | 13 | 8 | 5 | 0.699 |
| Non-SCC | 19 | 14 | 5 | |
| ECOG PS | ||||
| <2 | 30 | 20 | 10 | 1.000 |
| ≥2 | 2 | 2 | 0 | |
| Brain metastases | ||||
| Yes | 6 | 4 | 2 | 1.000 |
| No | 26 | 18 | 8 | |
| Liver metastases | ||||
| Yes | 4 | 4 | 0 | 0.283 |
| No | 28 | 18 | 10 | |
| Bone metastases | ||||
| Yes | 8 | 8 | 0 | 0.035 |
| No | 24 | 14 | 10 | |
| Smoking history | ||||
| Current/former | 26 | 18 | 8 | 1.000 |
| Never | 6 | 4 | 2 | |
| PD-L1 positivity | ||||
| <1% | 8 | 8 | 0 | 0.035 |
| 1–49% | 24 | 14 | 10 |
Data are represented by the mean ± SD or n.
ATA: anti-thyroid antibody
BMI: body mass index
SCC: squamous cell carcinoma
Non-SCC: non-squamous cell carcinoma
ECOG PS: Eastern Cooperative Oncology Group performance status
PD-L1: programmed cell death-1 ligand 1